Skip to main content

Articles

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO, Oncology
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Read More
Melanoma, Conference Highlights ASCO, Oncology
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
Wayne Kuznar
Read More
Prostate Cancer, Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Read More
Conference Highlights ASCO
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer
Wayne Kuznar
Read More
Renal-Cell Carcinoma, Conference Highlights ASCO, Oncology
Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
Read More
FDA Approvals
Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer
Read More
FDA Approvals
Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer
Read More
FDA Approvals
Trodelvy Receives New Indication for Advanced Urothelial Cancer
Read More
FDA Approvals
Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial
Read More
Page 21 of 244
Results 201 - 210 of 2434